Holen Sie sich die Stockscreener-App
3.64
4.21%
-0.16
Handel nachbörslich:
3.71
0.07
+1.92%
Schlusskurs vom Vortag:
$3.80
Offen:
$3.79
24-Stunden-Volumen:
899.46K
Relative Volume:
2.15
Marktkapitalisierung:
$104.96M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.14M
KGV:
-3.9565
EPS:
-0.92
Netto-Cashflow:
$-12.64M
1W Leistung:
+7.37%
1M Leistung:
+76.70%
6M Leistung:
+73.75%
1J Leistung:
+128.93%
1-Tages-Spanne:
$3.41
$3.90
1-Wochen-Bereich:
$3.40
$4.05
52-Wochen-Spanne:
$1.34
$4.05
Immix Biopharma Inc Stock (IMMX) Company Profile
Firmenname
Immix Biopharma Inc
Sektor
Branche
Telefon
(888) 958-1084
Adresse
11400 WEST OLYMPIC BLVD., LOS ANGELES
Vergleichen Sie IMMX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
3.64 | 125.53M | 0 | -14.14M | -12.64M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Immix Biopharma Inc Aktie (IMMX) Neueste Nachrichten
Immix Biopharma : Presentation (IMMX Corporate presentation November 2025) - MarketScreener
What analysts say about Immix Biopharma Inc stockTechnical Resistance Breaks & Affordable Portfolio Growth - earlytimes.in
Can trapped investors hope for a rebound in Immix Biopharma Inc.Bear Alert & Daily Stock Trend Watchlist - newser.com
How Immix Biopharma Inc. stock valuations compare to rivals2025 Price Targets & AI Forecast Swing Trade Picks - newser.com
How to manage a losing position in Immix Biopharma Inc.Trade Exit Summary & Capital Efficient Trading Techniques - newser.com
Immix Biopharma to present NXC-201 trial data for AL amyloidosis at ASH - Investing.com
Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025 - Investing News Network
Immix Biopharma (IMMX) ASH 2025 oral to feature NEXICART-2 first 20-patient data on Dec 7 - Stock Titan
How Immix Biopharma Inc. stock reacts to bond yieldsGap Up & Free Expert Approved Momentum Trade Ideas - newser.com
Immix Biopharma Inc (IMMX) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - setenews.com
Immix Biopharma Inc. stock volume spike explainedJuly 2025 Reactions & Free Safe Capital Growth Stock Tips - newser.com
What the charts say about Immix Biopharma Inc. today2025 Analyst Calls & Safe Entry Point Identification - newser.com
Why Immix Biopharma Inc. stock appeals to dividend seekersIPO Watch & Reliable Entry Point Alerts - newser.com
Will Immix Biopharma Inc. stock sustain high P E ratiosEarnings Miss & Daily Entry Point Alerts - newser.com
Immix Biopharma Inc. stock trendline breakdownTrade Analysis Report & Daily Volume Surge Signals - newser.com
Comparing Immix Biopharma Inc. in custom built stock radarsQuarterly Portfolio Report & Reliable Breakout Forecasts - newser.com
Risk adjusted return profile for Immix Biopharma Inc. analyzedMarket Performance Recap & Risk Controlled Stock Alerts - newser.com
Is Immix Biopharma Inc. stock a smart buy before Fed meeting2025 Market Outlook & Daily Stock Momentum Reports - newser.com
Is Immix Biopharma Inc. still worth holding after the dip2025 Volume Leaders & Technical Confirmation Trade Alerts - newser.com
Will Immix Biopharma Inc. see short term momentum2025 Major Catalysts & Capital Protection Trading Alerts - newser.com
Immix Biopharma (NASDAQ:IMMX) Trading Down 1.3%Time to Sell? - MarketBeat
Momentum divergence signals in Immix Biopharma Inc. chartJuly 2025 Decliners & Daily Stock Trend Reports - newser.com
Immix Biopharma’s NXC-201 CAR-T Study: A Potential Game-Changer for AL Amyloidosis - TipRanks
Finanzdaten der Immix Biopharma Inc-Aktie (IMMX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):